Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,501,190
  • Shares Outstanding, K 99,706
  • Annual Sales, $ 2,355 M
  • Annual Income, $ 341,300 K
  • EBIT $ 550 M
  • EBITDA $ 551 M
  • 60-Month Beta 0.28
  • Price/Sales 5.16
  • Price/Cash Flow 39.81
  • Price/Book 4.47

Options Overview Details

View History
  • Implied Volatility 36.02% (+1.75%)
  • Historical Volatility 28.24%
  • IV Percentile 60%
  • IV Rank 29.25%
  • IV High 69.08% on 04/08/25
  • IV Low 22.35% on 08/29/25
  • Expected Move (DTE 29) 10.36 (7.65%)
  • Put/Call Vol Ratio 28.25
  • Today's Volume 585
  • Volume Avg (30-Day) 498
  • Put/Call OI Ratio 1.50
  • Today's Open Interest 8,802
  • Open Int (30-Day) 8,861
  • Expected Range 125.16 to 145.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.83
  • Number of Estimates 7
  • High Estimate 2.18
  • Low Estimate 1.65
  • Prior Year 1.00
  • Growth Rate Est. (year over year) +83.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
129.17 +4.90%
on 01/20/26
148.56 -8.79%
on 12/23/25
-12.03 (-8.15%)
since 12/22/25
3-Month
129.17 +4.90%
on 01/20/26
160.18 -15.41%
on 12/08/25
-5.97 (-4.22%)
since 10/22/25
52-Week
84.23 +60.87%
on 04/09/25
160.18 -15.41%
on 12/08/25
-11.26 (-7.67%)
since 01/22/25

Most Recent Stories

More News
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results

Conference Call and Webcast Scheduled for Wednesday, February 11

NBIX : 136.14 (+0.54%)
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR

SAN DIEGO , Jan. 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first head-to-head data comparing vesicular monoamine transporter...

NBIX : 136.14 (+0.54%)
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO , Jan. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 44 th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Monday, January...

NBIX : 136.14 (+0.54%)
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy

SAN DIEGO , Dec. 22, 2025 /PRNewswire/ --  Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced that its Phase 3 KINECT ® -DCP study evaluating the efficacy, safety, and tolerability...

NBIX : 136.14 (+0.54%)
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology

Provided Update on R&D Engine Now On Track to Deliver Multiple First- and Best-in-Class Medicines, Positioning Company for Long-Term Value Creation Across Therapeutic Modalities

NBIX : 136.14 (+0.54%)
Neurocrine Biosciences to Host R&D Day on December 16

SAN DIEGO , Dec. 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00...

NBIX : 136.14 (+0.54%)
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules

SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of a comprehensive peer-reviewed narrative review that consolidates pharmacologic,...

NBIX : 136.14 (+0.54%)
Neurocrine Biosciences to Present at Upcoming Investor Conferences

SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:

NBIX : 136.14 (+0.54%)
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder

SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational...

NBIX : 136.14 (+0.54%)
Neurocrine: Q3 Earnings Snapshot

Neurocrine: Q3 Earnings Snapshot

NBIX : 136.14 (+0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 138.96
2nd Resistance Point 137.58
1st Resistance Point 136.49
Last Price 136.14
1st Support Level 134.02
2nd Support Level 132.64
3rd Support Level 131.55

See More

52-Week High 160.18
Last Price 136.14
Fibonacci 61.8% 131.17
Fibonacci 50% 122.21
Fibonacci 38.2% 113.24
52-Week Low 84.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar